Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is a leader in the regenerative biomaterial industry, with a strong track record and established relationships in the wound care and surgical markets. The company also has a best-in-class suite of clinical data to support the effectiveness and economic benefits of its amniotic tissue products. While the recent Medicare reimbursement changes have negatively impacted the company's sales, we believe that MiMedx is well-positioned to outperform in the new environment thanks to its vertically integrated manufacturing infrastructure and established sales force. Additionally, the company's recent restructuring and cost reduction initiative is expected to result in significant operating expense savings, further improving its financial outlook.

Bears say

MiMedx Group is facing challenges with reimbursement and declining sales in its key Wound Care segment due to changes in the CMS reimbursement policies. While management has implemented cost reduction initiatives and foresees a slow recovery, this disruption is expected to continue to have a negative impact on the company's top-line growth. Risks related to donorship, competition, and contracts with GPOs and IDNs also pose potential threats to the company's future business.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.